CID at JIM 2011

CID to Update Interventional Cardiologists on Cre8(TM) Drug Eluting Stent at the 2011 Joint Interventional Meeting

ROME, February 8, 2011 - CID spa, a European company leader in interventional medicine, will
present the key technologies implemented on CID's Cre8(TM) DES as well as all
the new preclinical data at the Joint Interventional Meeting (JIM) during the
Lunch Symposium "NEW DES: A NEW STEP FORWARD?" on Thursday, February 10,
2011.

Alexandre Abizaid, MD, PhD., Chief of Intervention at Instituto Dante
Pazzanese, in Sao Paulo, Brazil, in his presentation "New CID Polymer Free
Reservoirs and Bio-inducer DES" will point out the unique features of the
Cre8(TM) DES. The unique polymer-free Abluminal Reservoir Technology (ART)
together with the new Amphilimus(TM) formulation allows a controlled and
targeted drug elution to the vessel wall. The iCarbofilm bio-inducer surface
has been developed to lower the risk of thrombotic events and to avoid the
need for prolonged dual antiplatelet therapy.

Didier Carrie, MD, PhD, Head of Hemodynamics and Angioplasty at Toulouse
Teaching Hospital and Vice-Dean of the Faculty of Medicine in the "Cre8(TM):
Preclinical Experience and Clinical Plan" presentation will review all the
pre-clinical data on Cre8(TM). Prof. Carrie will also outline the design of
the randomized clinical study "NEXT", the results of which will be presented
at European PCR 2011.

Commenting on the innovative technology in its new Cre8(TM) DES, Franco
Vallana, Chief Executive Officer of CID s.p.a. said: "As we move closer to
launching our newest stent, it is important that cardiologists from around
the world are kept up to date on our innovative technologies with Cre8. The
total elimination of polymers, thanks to our Abluminal Reservoir Technology
(ART), and the use of a bio-inducer Carbon-coated surface, will certainly
benefit physicians and their patients."

For more information on CID Vascular, +39-0161-487338, Info at cidvascular.com, www at cidvascular.com